TY - JOUR
T1 - Quantifying the Employer Burden of Persistent Musculoskeletal Pain at a Large Employer in the United Kingdom:
T2 - A Non-interventional, Retrospective Study of Rolls-Royce Employee Data
AU - Roomes, David
AU - Abraham, Lucy
AU - Russell, Rachel
AU - Beck, C
AU - Halsby, K
AU - Wood, Robert
AU - O'Brien, M
AU - Massey, L
AU - Burton, Kim
N1 - Funding Information:
This study was sponsored by Pfizer and Eli Lilly and Company. Authors affiliated with Pfizer participated in designing the study, interpreting the data, and writing the manuscript, and approved the final version for publication. Medical writing and editorial support was provided by Deirdre Carman PhD (Alispera Communications Ltd) and was funded by Pfizer and Eli Lilly and Company.
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - OBJECTIVE: To quantify the burden of work-relevant persistent musculoskeletal (MSK) pain to a large UK employer. METHODS: A retrospective, longitudinal, analytical cohort study using linked Rolls-Royce data systems. Cases were employees with a MSK-related referral to occupational health; controls were age-, sex-, and job role-matched employees without such a referral. Outcomes were compared during 12 months' follow-up. RESULTS: Overall, 2382 matched case-control pairs were identified (mean age: 46 y; 82% male). Cases took 39,200 MSK-related sickness absence days in total (equating to £50 million in sickness absence costs). Cases took significantly more all-cause sickness absence days than controls (82,341 [£106 million] versus 19,628 [£26 million]; P < 0.0001). CONCLUSIONS: Despite access to extensive occupational health services, the burden of work-relevant persistent MSK pain remains high in Rolls-Royce. There is a clear need to better understand how to effectively reduce this burden.
AB - OBJECTIVE: To quantify the burden of work-relevant persistent musculoskeletal (MSK) pain to a large UK employer. METHODS: A retrospective, longitudinal, analytical cohort study using linked Rolls-Royce data systems. Cases were employees with a MSK-related referral to occupational health; controls were age-, sex-, and job role-matched employees without such a referral. Outcomes were compared during 12 months' follow-up. RESULTS: Overall, 2382 matched case-control pairs were identified (mean age: 46 y; 82% male). Cases took 39,200 MSK-related sickness absence days in total (equating to £50 million in sickness absence costs). Cases took significantly more all-cause sickness absence days than controls (82,341 [£106 million] versus 19,628 [£26 million]; P < 0.0001). CONCLUSIONS: Despite access to extensive occupational health services, the burden of work-relevant persistent MSK pain remains high in Rolls-Royce. There is a clear need to better understand how to effectively reduce this burden.
KW - Cost analysis
KW - disease burden
KW - musculoskeletal pain
KW - retrospective
KW - sickness absence
KW - cost analysis
UR - http://www.scopus.com/inward/record.url?scp=85125682570&partnerID=8YFLogxK
U2 - 10.1097/JOM.0000000000002468
DO - 10.1097/JOM.0000000000002468
M3 - Article
VL - 64
SP - e145-e154
JO - Journal of Occupational and Environmental Medicine
JF - Journal of Occupational and Environmental Medicine
SN - 1076-2752
IS - 3
ER -
